Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up – Here’s What Happened

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares gapped up before the market opened on Friday . The stock had previously closed at $27.27, but opened at $29.66. Collegium Pharmaceutical shares last traded at $29.02, with a volume of 16,253 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on COLL. Piper Sandler reiterated a “neutral” rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday. Needham & Company LLC reiterated a “buy” rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.

Collegium Pharmaceutical Trading Up 5.9 %

The business has a 50 day simple moving average of $28.10 and a 200 day simple moving average of $30.03. The company has a market cap of $928.29 million, a price-to-earnings ratio of 12.45 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now directly owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,693 shares of company stock valued at $2,334,994. Company insiders own 2.51% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in shares of Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of Collegium Pharmaceutical by 8.5% in the fourth quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company’s stock valued at $573,000 after purchasing an additional 1,558 shares during the last quarter. Barclays PLC increased its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after buying an additional 45,291 shares during the period. Principal Financial Group Inc. raised its stake in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 5.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company’s stock valued at $542,000 after buying an additional 952 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.